PSMC5
ENSG00000087191
Target class
Enzyme
Chromosome
17
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- PSMC5
- Gene name
- Proteasome 26S subunit, ATPase 5
- Gene symbol
- PSMC5
- Protein name
- 26S proteasome regulatory subunit 8 (26S proteasome AAA-ATPase subunit RPT6) (Proteasome 26S subunit ATPase 5) (Proteasome subunit p45) (Thyroid hormone receptor-interacting protein 1) (TRIP1) (p45/SUG)
- SUG1
- p45/SUG
- TBP10
- p45
- S8
- TRIP1
- SUG-1
- RPT6
- Gene biotype
- Protein coding
- Gene family
- AAA ATPases|Proteasome
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 253.39
- Tissue specificity (Gini)
- 0.164
- Tissue specificity (tau)
- 0.366
- KEGG gene identifiers
- hsa:5705
- Protein interaction confidence
- 0.895736
- Protein interaction partners
- 91
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 42 more, listed on the interactive page.
- End position
- 63832244
- Start position
- 63827152
- Chromosome
- 17
- Strand
- Forward
- Cytoplasm . Nucleus .
- Cytosol
- Plasma membrane
- Tissue specificity (tau)
- 0.3655
- Expression inequality (Gini)
- 0.163648
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 253.39
- Testis
- 238.17
- Brain - Cerebellum
- 232.34
- Esophagus - Gastroesophageal Junction
- 222.42
- Nerve - Tibial
- 219.98
Expression in transcripts per million
- Brain - Cerebellar Hemisphere253.39
- Testis238.17
- Brain - Cerebellum232.34
- Esophagus - Gastroesophageal Junction222.42
- Nerve - Tibial219.98
- Fallopian Tube217.45
- Colon - Sigmoid214.52
- Esophagus - Muscularis213.72
- Artery - Tibial213.08
- Cervix - Ectocervix211.29
- Cervix - Endocervix211.29
- Thyroid208.08
- Artery - Aorta203.14
- Pituitary203
- Uterus202.76
- Prostate199.76
- Bladder198.1
- Artery - Coronary194.41
- Skin - Sun Exposed (Lower leg)192.83
- Skin - Not Sun Exposed (Suprapubic)192.31
- Muscle - Skeletal180.4
- Vagina177.49
- Brain - Frontal Cortex (BA9)175.86
- Spleen171.99
- Cells - Cultured fibroblasts164.99
And 29 more, listed on the interactive page.
- GO:0006357
- GO:0043161
- GO:1901800
- GO:0000502
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0016020
- GO:0031410
- GO:0070062
- GO:0072562
- GO:0005515
- GO:0008134
- GO:0031531
- GO:0036402
- GO:0140296
- GO:0140297
Related records
Trials (789)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (5)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor